It’s been a wild ride for investors in Telix Pharmaceuticals Ltd (ASX: TLX) shares. The biotech star surged to a high of $29.72 nearly a year ago, only to tumble around 56% to $12.29 at the time of writing.
That kind of volatility might scare some investors away. But for others, it raises a more intriguing question: Could Telix shares become a long-term winner and turn $50,000 into a $1,000,000?
A different growth story
Telix isn’t your typical early-stage biotech. The company develops radiopharmaceuticals used in cancer diagnosis and treatment. It operates in a niche combining precision medicine with complex manufacturing and global distribution.
Importantly, Telix has already transitioned into full commercial operations. That sets it apart from many speculative biotech plays still waiting on approvals.
As more of its products gain regulatory clearance and clinical adoption increases, revenue has the potential to scale rapidly. In other words, future growth is less about macroeconomic conditions and more about how quickly its therapies are adopted.
That dynamic can create sharp price swings, as seen recently with Telix shares. But it also offers direct exposure to a high-growth corner of healthcare.
Revenue is booming
Telix’s latest results show just how quickly the business is expanding.
Last month, the company reported full-year revenue of US$803 million, up 56% year on year and at the lower end of its upgraded guidance range.
Even more impressive, it expects to generate between US$950 million and US$970 million in revenue this year. That would push it comfortably beyond the $1 billion mark.
At the same time, Telix is continuing to invest heavily in future growth, with research and development spending forecast at US$200 million to US$240 million.
This combination of strong revenue growth and continued innovation is exactly what long-term investors in Telix shares want to see.
Major opportunity, limited competition
One of the most exciting developments is Telix’s progress in brain cancer.
The company recently submitted a European marketing application for TLX101-Px, an imaging agent designed for glioblastoma â one of the most aggressive and difficult-to-treat cancers.
This week, Telix resubmitted its New Drug Application to the U.S. FDA for TLX101-Px, including new data addressing prior feedback and supporting approval.
Crucially, there are currently no widely available commercial alternatives. That gives Telix a rare opportunity to address an urgent medical need with limited direct competition.
If successful, this could become a meaningful growth driver for Telix shares in the years ahead.
What do analysts think?
Despite the share price slump, sentiment remains overwhelmingly positive on Telix shares.
According to TradingView data, all 16 analysts covering ASX biotech stock rate it as a buy or strong buy. Average 12-month price targets suggest Telix shares could climb around 95% to $23.97, with the most bullish forecasts pointing to as high as $31.59. This points to a potential upside of more than 150%.
That’s a remarkable level of confidence for a stock that has fallen so sharply.
Foolish Takeaway
There’s no doubt Telix shares carry risk. Biotech stocks are inherently volatile, and success depends on execution, approvals, and market uptake.
But with surging revenues, a growing commercial footprint, and exposure to a high-value medical niche, Telix has the ingredients of a powerful long-term growth story.
If it can deliver on its pipeline and scale globally, today’s weakness could one day look like an opportunity. The kind that patient investors have million-dollar dreams about.
The post Could Telix shares be a millionaire-maker stock? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Telix Pharmaceuticals right now?
Before you buy Telix Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Here are the top 10 ASX 200 shares today
- 3 ASX healthcare stocks tipped to soar over 100% higher this year
- Why are Telix shares racing 8% higher today?
- Here are the top 10 ASX 200 shares today
- 3 ASX shares tipped to race up to 188% higher
Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.